Moleculin Biotech MBRX 深 滬
已收盤 08-07 16:00:00 美东时间
0.4095
+0.025
+6.36%
華盛通- 最 高0.415
- 今 開0.386
- 成交量 100.14万股
- 最 低 0.3805
- 昨 收 0.385
- 總市值 290.77万
- 52周最高 17.225
- 市盈率 靜 --
- 換手率 14.10%
- 52周最低 0.1614
- 委 比 -5.82%
- 總股本 710.07万
- 歷史最高 21555.00
- 量 比 0.15
- 振 幅 8.96%
- 歷史最低 0.1614
- 每 手 1
- 風險率 4.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moleculin Biotech completes $9.3M equity financing
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On July 31, 2026, Mol...
08-04 06:22
Moleculin Announces Pricing of $9.3 Million Public Offering
Moleculin Biotech announced a public offering of 12.4 million shares and warrants for up to 37.1 million shares at $0.75 per share, expected to close on August 3. Proceeds will fund the clinical development of Annamycin and working capital. Roth Capital Partners is the placement agent, and Maxim Group is the financial advisor. Annamycin is in Phase 3 for relapsed/refractory acute myeloid leukemia and soft tissue sarcoma.
07-31 14:12
Moleculin Biotech shares are trading lower. The company announced a best‑efforts public offering of stock and warrants, including pre‑funded options to cap ownership.
Moleculin Biotech shares are trading lower. The company announced a best‑efforts public offering of stock and warrants, including pre‑funded options to cap ownership.
07-30 02:57
Why is Moleculin Stock Falling Today?
Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did not reach statistical significance. However, the company noted that both Annamycin t...
07-01 02:00
Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-treat basis with no patient exclusions....
06-30 20:34
Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting
The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," highlighted findings from a pooled analysis across five completed clinical trials evaluating
05-29 20:26
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Moleculin Biotech's lead drug candidate, Annamycin, demonstrated a differentiated cardiac safety profile in a pooled analysis of five clinical trials, with no detectable cardiotoxicity even at high cumulative doses. The findings, presented at the 2026 ASCO Annual Meeting, were independently reviewed by Cleveland Clinic cardiologists. Annamycin showed no significant change in left ventricular ejection fraction (LVEF) and no correlation between dos...
05-29 12:21
